Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications
Monlunabant in adults with obesity and metabolic syndrome: Open-label extension of a phase 2a trial.
Monlunabant in adults with obesity and metabolic syndrome: Open-label extension of a phase 2a trial.
Journal: Diabetes, obesity & metabolism
Published: December 12, 2025
A double-blind, randomized, placebo-controlled, phase 2 trial examined the efficacy and safety of monlunabant in adults with diabetic kidney disease.
Journal: Kidney international
Published: September 30, 2025
A cannabinoid receptor 1 inverse agonist induces weight loss and reduces airway hyperresponsiveness in a mouse model of obese asthma.
Journal: American journal of physiology. Lung cellular and molecular physiology
Published: July 24, 2025
Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial.
Journal: The lancet. Diabetes & endocrinology
Published: March 18, 2025
Blockade of cannabinoid CB1 receptors potentiates the anti-fibrotic effects mediated by SGLT2 inhibition in a mouse model of diabetic nephropathy.
Journal: British journal of pharmacology
Published: January 20, 2025
Effects of CB1R inverse agonist, INV-202, in patients with features of metabolic syndrome. A randomized, placebo-controlled, double-blind phase 1b study.
Journal: Diabetes, obesity & metabolism
Published: July 24, 2023
Therapeutic potential of a novel peripherally restricted CB1R inverse agonist on the progression of diabetic nephropathy.
Journal: Frontiers in nephrology
Published: January 05, 2023
Lung deposition of inhaled once-daily long-acting muscarinic antagonists via standard jet nebulizer or dry powder inhaler, measured using functional respiratory imaging, in patients with chronic obstructive pulmonary disease.
Journal: Therapeutic advances in respiratory disease
Published: March 02, 2022
Clinical Burden of Chronic Obstructive Pulmonary Disease in Patients with Suboptimal Peak Inspiratory Flow.
Journal: Canadian respiratory journal
Published: January 11, 2022
A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19.
Journal: The European respiratory journal
Published: March 05, 2021
Safety and Efficacy of Revefenacin and Formoterol in Sequence and Combination via a Standard Jet Nebulizer in Patients with Chronic Obstructive Pulmonary Disease: A Phase 3b, Randomized, 42-Day Study.
Journal: Chronic obstructive pulmonary diseases (Miami, Fla.)
Published: April 24, 2020
Last Updated: 09/26/2026